...
首页> 外文期刊>European Journal of Inflammation >Effects of dexmedetomidine on renal function in patients with septic shock:
【24h】

Effects of dexmedetomidine on renal function in patients with septic shock:

机译:右美托咪定对败血性休克患者肾功能的影响:

获取原文
   

获取外文期刊封面封底 >>

       

摘要

This study was to observe the effects of dexmedetomidine against acute kidney injury in patients with septic shock. A prospective randomized controlled trial (RCT) was conducted in which 80 patients with septic shock admitted in Department of Critical Care Medicine of the Affiliated Hospital of Chengdu University from June 2015 to January 2017 were divided into experimental group and control group. The patients in both groups received basic treatment for septic shock, and the patients in the experimental group were given intravenous injection of dexmedetomidine, maintained with 0.1–0.2?μg?kg?1?h?1 for 5?days. In both groups, the changes in the levels of interleukin (IL)-6, tumor necrosis factor (TNF)-α, serum creatinine (SCr), cystatin C (Cys C), and β2-microglobulin (β2-MG) were determined before treatment and 1, 3, and 5?days after treatment. At 5?days after treatment, Cys C, β2-MG, and SCr were significantly decreased in both groups (P??0.05), and the degree of decrease in the experimental group was more obvious (P??0.05). At 1, 3, and 5?days after treatment, IL-6 and TNF-α were significantly decreased in both groups (P??0.05) and the degree of decrease in the experimental group was more obvious (P??0.05). Dexmedetomidine has certain renal protective effect in patients with septic shock, and its mechanism is possibly related to the regulation and improvement of uncontrolled inflammatory response.
机译:本研究旨在观察右美托咪定对败血性休克患者急性肾损伤的影响。一项前瞻性随机对照试验(RCT)将2015年6月至2017年1月在成都大学附属医院重症医学科收治的80例脓毒性休克患者分为实验组和对照组。两组患者均接受了败血性休克的基础治疗,实验组患者静脉注射右美托咪定,维持0.1-0.2?g?kg?kg?1?h?1,持续5天。两组均测定了白介素(IL)-6,肿瘤坏死因子(TNF)-α,血清肌酐(SCr),胱抑素C(Cys C)和β2-微球蛋白(β2-MG)水平的变化治疗前,治疗后1、3和5天。治疗后第5天,两组的Cys C,β2-MG和SCr均显着下降(P 0.05),实验组的下降程度更明显(P 0.05)。治疗后第1、3和5天,两组IL-6和TNF-α均显着下降(P 0.05),实验组下降程度更明显(P 0.05)。 )。右美托咪定对败血性休克患者具有一定的肾脏保护作用,其机制可能与调节和改善炎症反应不受控制有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号